Molecular Insight into Gut Microbiota and Rheumatoid Arthritis

Xiaohao Wu, Bing He, Jin Liu, Hui Feng, Yinghui Ma, Defang Li, Baosheng Guo, Chao Liang, Lei Dang, Luyao Wang, Tian Jing, Hailong Zhu, Lianbo Xiao, Cheng Lü, Aiping Lü, Ge ZhangInternational Journal of Molecular Sciences 2016 · DOI

TL;DR

This review explores the intricate relationship between the gut microbiota and Rheumatoid Arthritis (RA), a systemic autoimmune disease. It highlights how alterations in gut microbial composition (dysbiosis) can contribute to RA pathogenesis through various molecular mechanisms, suggesting potential new avenues for diagnosis and treatment.

What Problem Does This Paper Address?

Rheumatoid Arthritis (RA) is a complex autoimmune disease with a multifactorial etiology, involving both genetic and environmental factors. While the role of environmental factors like smoking and diet is recognized, the specific contribution of the gut microbiota to RA pathogenesis has been an area of growing interest and investigation. This paper addresses the need for a comprehensive understanding of the correlations and underlying molecular mechanisms linking gut microbiota, the immune system, and RA, aiming to bridge the gap between current knowledge and potential clinical applications.

Methods

This paper is a review article, meaning it synthesizes existing research rather than presenting new experimental data. The authors primarily rely on:

  • Literature Review: They systematically reviewed published studies, including those utilizing culture-independent DNA sequencing technologies (like 16S rRNA gene sequencing and metagenomic shotgun sequencing) to analyze fecal, dental, and salivary microbiomes.
  • Correlation Analysis: The review focuses on identifying correlations between specific gut microbial alterations and the presence or severity of RA.
  • Mechanistic Exploration: The authors discuss proposed molecular mechanisms by which gut microbiota might influence immune responses and contribute to RA development, drawing from studies on animal models and human immune cells.

Datasets

Not discussed in the paper. The paper is a review of existing literature and does not present its own datasets.

Key Insights and Ideas

  • Gut Microbiota as an "Additional Organ": The gut microbiota is increasingly viewed not just as a collection of microbes but as a functional entity that significantly impacts host health, akin to an organ.
  • Dysbiosis as a Key Player: Alterations in the composition and function of the gut microbiota (dysbiosis) are strongly implicated in the development and progression of RA.
  • Molecular Mechanisms of Influence: Gut microbes can influence RA pathogenesis through various pathways, including:
  • Short-Chain Fatty Acid (SCFA) Production: SCFAs, like butyrate, produced by gut bacteria, play a crucial role in immune system development and function, including the differentiation of regulatory T cells (Treg).
  • Immune Cell Modulation: Specific bacteria, such as Bacteroides fragilis (via polysaccharide A) and Segmented Filamentous Bacteria (SFB), can directly influence the differentiation and activation of T helper 17 (Th17) cells, which are key players in inflammatory responses.
  • Inflammatory Cytokine Production: Th17 cells, influenced by gut microbiota, produce pro-inflammatory cytokines like IL-17, which are central to RA pathology, promoting pannus growth, osteoclastogenesis, and synovial neoangiogenesis.
  • Microbial Translocation: Changes in the gut barrier function, potentially influenced by dysbiosis, can lead to the translocation of bacteria or their products into the bloodstream, triggering systemic inflammation.
  • Potential for Targeted Therapies: The identification of specific microbial culprits (e.g., Prevotella copri) and mechanisms opens doors for developing novel therapeutic strategies, such as probiotics, prebiotics, or even fecal microbiota transplantation, to modulate the gut microbiota for RA treatment.
  • Reversibility of Dysbiosis: Some studies suggest that gut microbial alterations associated with RA may be partially reversible with disease-modifying anti-rheumatic drugs (DMARDs), hinting at a dynamic interplay.

Key Results

  • Studies have identified significant differences in gut microbiota composition between RA patients and healthy individuals, with specific bacterial taxa being either enriched or depleted.
  • The expansion of Prevotella copri has been positively correlated with new-onset untreated RA and may be suppressed with RA treatment.
  • Alterations in gut microbial communities have been associated with clinical indices of RA, such as autoantibody titers.
  • Animal models demonstrate that specific gut bacteria can induce or exacerbate autoimmune arthritis, highlighting a causal link.
  • The review emphasizes that understanding the dynamic interaction between gut microbiota and the host immune system is crucial for developing individualized RA management strategies and discovering new drugs.

Limitations and Future Work

  • Limited Sample Sizes: The authors acknowledge that many of the reviewed studies have limited sample sizes, which may not fully represent the true alterations in gut microbiota in RA patients. More extensive data is needed for definitive characterization.
  • Defining "Dysbiosis": A key challenge remains in precisely defining what constitutes "dysbiotic" gut microbiota in the context of RA and how to reliably identify these specific microbial signatures.
  • Mechanistic Elucidation: While several molecular mechanisms are proposed, the exact role of gut microbiota in RA etiology is still under intense investigation, and more mechanistic studies are required.
  • Specificity of Drug Targets: Current RA medications are not specifically designed to target pathogen-like gut microbiomes, leading to a lack of specificity. Future research needs to focus on developing drugs that can precisely target these microbial imbalances.
  • Unexpected Drug Effects: The authors note that current medications, including NSAIDs and antibiotics, can have unintended effects on the gut microbiota, potentially complicating treatment outcomes.
  • Future Directions: The paper strongly advocates for well-designed investigations to characterize gut microbiota and their contribution to RA pathogenesis. This includes developing new strategies for targeting or manipulating the gut microbiota to restore ecological homeostasis and achieve therapeutic effects, ultimately leading to the discovery of new RA drugs.

Summary updated

Abstract

Rheumatoid arthritis (RA) is a systemic, inflammatory, and autoimmune disorder. Gut microbiota play an important role in the etiology of RA. With the considerable progress made in next-generation sequencing techniques, the identified gut microbiota difference between RA patients and healthy individuals provides an updated overview of the association between gut microbiota and RA. We reviewed the reported correlation and underlying molecular mechanisms among gut microbiota, the immune system, and RA. It has become known that gut microbiota contribute to the pathogenesis of RA via multiple molecular mechanisms. The progressive understanding of the dynamic interaction between gut microbiota and their host will help in establishing a highly individualized management for each RA patient, and achieve a better efficacy in clinical practice, or even discovering new drugs for RA.
BibTeX
@article{wu2016molecular,
  author = {Xiaohao Wu and Bing He and Jin Liu and Hui Feng and Yinghui Ma and Defang Li and Baosheng Guo and Chao Liang and Lei Dang and Luyao Wang and Tian Jing and Hailong Zhu and Lianbo Xiao and Cheng Lü and Aiping Lü and Ge Zhang},
  title = {{Molecular Insight into Gut Microbiota and Rheumatoid Arthritis}},
  journal = {International Journal of Molecular Sciences},
  year = {2016},
  doi = {10.3390/ijms17030431},
}
Figure